USANA Health Sciences (NYSE:USNA) Sets New 1-Year Low – Should You Sell?

USANA Health Sciences, Inc. (NYSE:USNA) hit a new 52-week low during trading on Tuesday . The company traded as low as $26.74 and last traded at $26.87, with a volume of 26579 shares changing hands. The stock had previously closed at $27.24.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. DA Davidson reduced their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Finally, StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th.

USANA Health Sciences Trading Up 3.7 %

The firm has a 50-day moving average of $31.39 and a two-hundred day moving average of $35.20. The firm has a market cap of $514.82 million, a price-to-earnings ratio of 9.62, a PEG ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, equities analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In related news, insider Joshua Foukas sold 5,732 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total transaction of $186,519.28. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Mulham Mulham sold 3,234 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the completion of the transaction, the insider now directly owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. This trade represents a 20.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,920 shares of company stock valued at $500,285 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Institutional Trading of USANA Health Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quest Partners LLC acquired a new stake in USANA Health Sciences during the third quarter worth $250,000. Martingale Asset Management L P lifted its holdings in shares of USANA Health Sciences by 2.1% during the 3rd quarter. Martingale Asset Management L P now owns 16,732 shares of the company’s stock worth $634,000 after acquiring an additional 340 shares during the period. Centiva Capital LP acquired a new stake in shares of USANA Health Sciences during the 3rd quarter valued at about $213,000. Safe Harbor Fiduciary LLC bought a new stake in USANA Health Sciences in the third quarter valued at about $30,000. Finally, State Street Corp raised its position in USANA Health Sciences by 0.6% in the third quarter. State Street Corp now owns 435,164 shares of the company’s stock worth $16,501,000 after purchasing an additional 2,782 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.